{
  "docId": "019de076-f846-767d-9b7f-8682a04c3e89",
  "docSlug": "d28195e1bb64bc51ad898953c5c30263",
  "documentTitle": "Boundless Bio | IPO Presentation Deck | 51 slides",
  "authorId": "boundless-bio",
  "authorName": "Boundless Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 32,
  "pageCount": 51,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a process flow diagram to illustrate the progression from single-agent to combination therapy trials.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-f846-767d-9b7f-8682a04c3e89/32",
  "deckHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89",
  "deckJsonHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89.json",
  "deckAnchorHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.95,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Flowchart showing Part 1 (Single agent), Part 2 (Combination), and Part 3 (Expansion baskets)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e9167a2-067f-4db4-8c49-fd051994a395",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Q2D: every other day; 2ON/5OFF: 2 days on, 5 days off; HGSOC: High-grade serous ovarian carcinoma; MTD: Maximum Tolerated Dose; RP2D: Recommended Phase 2 Dose; 1) Patients with known pathogenic driver mutations or fusions of ANY oncogene are excluded; 2) Part 3 sample size calculation per Simon's optimal two-stage design (Goal 1st stage RR ≥ 2/23)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47d10cf2-b186-48fa-bc03-98cbf11d84f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.95,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "table",
      "text": "Predictive biomarkers and objectives for each study part",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50735d51-90c1-4d58-a744-753763b58ce2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Phase 1/2 study of BBI-355 designed to drive to clinical proof of concept in multiple settings",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7dfe58f-a402-44a3-8cb5-dd151faa21aa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "08d8d4ed-fd93-4635-b945-23dc79689450",
      "evidence": "The slide uses a flow-based diagram to show the progression of clinical trial stages.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}